Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This ...

Habana still has some way to go to reach the top of the international try-scoring ranks, however. Japan wing Daisuke Ohata heads the list with 69 in 58 Tests, followed by Australian David Campese who ...